Heavy-drinking in middle-age has a greater influence on stroke than traditional risk factors
the ONA take:
In a study consistent with the American Heart Association’s recommended limits for alcohol consumption, researchers conclude that drinking more than two alcoholic beverages daily in middle-age may risk your stroke risk more than traditional factors such as high blood pressure and diabetes.
The researchers followed 11,644 middle-age Swedish twins for 43 years, comparing the effects of heavy drinking (more than two drinks daily) with light drinking (less than half a drink daily). Previous studies have shown that alcohol consumption affects stroke risk; however, this study demonstrated how age influences that risk.
Mid-life heavy drinkers (ages 50s to 60s) were likely to have a stroke 5 years earlier in life irrespective of genetic and early life factors, and their increased stroke risk compared to well-known risk factors such as high blood pressure and diabetes.
At approximately age 75 years, blood pressure and diabetes appeared to become the main influences on having a stroke.
Drinking more than two alcoholic beverages daily in middle-age may risk your stroke risk.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|